Welcome to our dedicated page for CollPlant Biotechnologies SEC filings (Ticker: CLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CollPlant Biotechnologies Ltd. filings document foreign private issuer current reports for a regenerative and aesthetic medicine company built around plant-derived rhCollagen. Form 6-K reports cover operating and financial results, corporate updates on BioInk, Collink.3D, BioFlex, Vergenix STR and photocurable dermal filler technology, as well as intellectual-property disclosures and collaboration-related material events.
The filing record also documents capital-structure matters involving ordinary shares and warrants, Nasdaq Capital Market bid-price compliance notices, and material agreements. Certain 6-K reports are incorporated by reference into the company’s Form S-8 and Form F-3 registration statements, linking current-event disclosures to equity compensation and shelf-registration records.
CollPlant Biotechnologies Ltd. files a Form F-3 prospectus to register 31,047,068 ordinary shares for resale by selling shareholders.
The registration covers 4,464,707 PIPE Shares and 26,582,361 ordinary shares issuable upon exercise of warrants issued in a June 29, 2026 private placement that closed on July 6, 2026. The prospectus states the Company will not receive proceeds from resales but would receive cash if warrants are exercised; full cash exercise of the outstanding warrants would yield approximately $8.0 million.
CollPlant Biotechnologies Ltd. is calling an extraordinary general meeting to seek shareholder approval for a major increase in its authorized share capital. The proposal would raise authorized Ordinary Shares from 30,000,000 to 500,000,000, each with a par value of NIS 1.50, and amend the Memorandum and Articles of Association accordingly.
The Board states this larger capacity would support obligations from private placement agreements signed in June 2026, which involve units of shares and warrants, and provide flexibility for future strategic transactions. Shareholders of record on July 9, 2026 may vote at the July 29, 2026 meeting in Tel-Aviv.
As of July 6, 2026, 18,908,207 Ordinary Shares were outstanding, excluding 18,409 held in treasury, each carrying one vote. A quorum requires at least 20% of outstanding Ordinary Shares present in person or by proxy, and the Board recommends voting in favor of the proposal.
CollPlant Biotechnologies entered into a definitive securities purchase agreement for a $2.6 million private placement. The deal covers 7,647,061 ordinary shares (or pre-funded warrants in lieu) plus unregistered series A and series B warrants, all priced at $0.34 per share and accompanying warrants (or $0.3399 per pre-funded warrant and accompanying warrants).
The series A and B warrants each have a $0.34 exercise price, become exercisable on the shareholder approval date, and have terms of two and five years, respectively, after effectiveness of a resale registration statement. CollPlant plans to use the net proceeds for general corporate purposes, working capital, research and development, and to continue evaluating strategic business combinations.
H.C. Wainwright & Co. is acting as exclusive placement agent and will receive cash fees, expense reimbursements, and placement agent warrants to purchase up to 458,824 ordinary shares at $0.425 per share. The securities are being issued in a private placement under U.S. Securities Act exemptions, with CollPlant agreeing to file a resale registration statement for the shares and warrant shares.
CollPlant Biotechnologies reported weak first quarter 2026 results and outlined strategic and R&D updates. Revenue fell to $73,000 from $2.055 million a year earlier, mainly because a $2.0 million milestone payment in Q1 2025 did not repeat. GAAP net loss widened to $3.1 million, or $0.23 per share, versus a $1.5 million loss, or $0.13 per share, in Q1 2025. Cash and cash equivalents were $4.3 million as of March 31, 2026, with $3.0 million used in operating activities in the quarter.
The company implemented a cost reduction plan, cutting headcount by about 50%, which helped lower operating expenses to $2.9 million from $3.5 million. CollPlant is advancing a next-generation photocurable dermal filler platform in final preclinical stages and launched its BioFlex rhCollagen-based bioprinting kit. Management also began evaluating strategic alternatives, including potential acquisitions, strategic transactions and other business combinations, with no decisions or timetable yet.
CollPlant Biotechnologies Ltd director Hugh M. Evans filed an initial ownership report showing his equity stake in the company. He directly holds 315,554 Ordinary Shares and 10,000 Restricted Share Units, of which 3,125 are vested and 6,875 vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, subject to continued service.
Evans also holds two option awards to purchase Ordinary Shares: 24,000 options and 23,000 options, each with an exercise price of $6.39 per share and expiration dates on May 2, 2032 and May 26, 2031, respectively. One grant is fully vested, while 22,500 options from the other grant are vested and the remainder vest on May 2, 2026, subject to continued service. Additional Ordinary Shares are held indirectly: shares beneficially owned by his spouse and shares held by an irrevocable trust for his children, for which he disclaims beneficial ownership.
CollPlant Biotechnologies Ltd. is registering for resale up to 3,296,000 ordinary shares issuable upon exercise of private placement warrants (1,600,000 series A; 1,600,000 series B; 96,000 placement agent warrants). This registration is a resale registration by the selling shareholders; the company will not receive proceeds from resale.
The prospectus names the selling shareholders and notes ordinary shares outstanding of 14,415,128 as of March 17, 2026. The company may receive proceeds only if the warrants are exercised for cash (full cash exercise would yield approximately $4.15 million). Trading symbol: CLGN; last reported sale price: $0.37 per share (April 20, 2026).
CollPlant is registering 3,296,000 ordinary shares for resale by selling shareholders, representing shares issuable upon exercise of private placement warrants.
The prospectus states we will not receive proceeds from resale; however, the company may receive up to $4.15 million if the Private Placement Warrants are exercised for cash. Shares outstanding were 14,415,128 ordinary shares as of March 17, 2026.
CollPlant Biotechnologies reported that Allergan Industrie SAS, an AbbVie company, has exercised its right to terminate their February 2021 development agreement for a dermal and soft tissue filler based on CollPlant’s rhCollagen technology, with termination effective June 8, 2026.
In response, CollPlant is implementing a cost-reduction and workforce optimization plan, cutting its workforce by approximately 50%, which it believes will extend its cash runway into Q4 2026. The company is pursuing new strategic partnerships in aesthetic products, advancing three core programs in regenerative dermal and soft tissue fillers, regenerative breast implants, and rhCollagen bioinks for 3D bioprinting.
CollPlant Biotechnologies Ltd. is registering up to 3,296,000 ordinary shares for resale by selling shareholders, representing shares issuable upon exercise of warrants issued in connection with its February 2026 financing. The prospectus states the company will not receive proceeds from these resales; however, it may receive approximately $4.15 million if the warrants are exercised for cash in full.
The filing discloses 14,415,128 ordinary shares outstanding as of March 17, 2026, lists plan of distribution options for selling shareholders, and provides customary registration and risk disclosures.